Is RAGE still a therapeutic target for Alzheimers disease?

Future Medicinal Chemistry

Volumn 4, Issue 7, 2012, Pages 915-925

  Deane, Richard J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST; AMYLOID BETA PROTEIN; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; INFLAMMATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN CONFORMATION; PROTEIN ISOFORMS; RECEPTORS, IMMUNOLOGIC;

EID: 84861050637     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.51     Document Type: Review

References (78)

1. Yan SD, Chen X, Fu J et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382(6593), 685-691 (1996). Key paper on receptor for advanced glycation end products (RAGE)-Amyloid-b (Ab) in Alzheimer's disease.
2. Koch M, Chitayat S, Dattilo BM et al. Structural basis for ligand recognition and activation of RAGE. Structure 18(10), 1342-1352 (2010). Key paper on the molecular structure of RAGE and its interaction with ligands.
3. Fritz G. RAGE: A single receptor fits multiple ligands. Trends Biochem. Sci. 36(12), 625-632 (2011). Good review on RAGE-ligand interaction.
4. Neeper M, Schmidt AM, Brett J et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267(21), 14998-15004 (1992
5. Deane R, Du Yan S, Submamaryan RK et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9(7), 907-913 (2003). Key paper on RAGE/blood-brain barrier interaction.
6. Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: Therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem. Pharmacol. 79(10), 1379-1386 (2010). Reviews RAGE as a therapeutic target.
7. Schmidt AM, Vianna M, Gerlach M et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267(21), 14987-14997 (1992
8. Ramasamy R, Yan SF, Schmidt AM. Advanced glycation endproducts: From precursors to RAGE: Round and round we go. Amino Acids 42(4), 1151-1161 (2010
9. Leclerc E, Fritz G, Vetter SW, Heizmann CW. Binding of S100 proteins to RAGE: An update. Biochim. Biophys. Acta 1793(6), 993-1007 (2009
10. Ramasamy R, Yan SF, Schmidt AM. RAGE: Therapeutic target and biomarker of the inflammatory response - the evidence mounts. J. Leukoc. Biol. 86(3), 505-512 (2009). Develops the possibility of RAGE as a therapeutic target.
11. Pullerits R, Brisslert M, Jonsson IM, Tarkowski A. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum. 54(12), 3898-3907 (2006
12. He M, Kubo H, Morimoto K et al. Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO J. 12(4), 358-364 (2011
13. Yamamoto Y, Harashima A, Saito H et al. Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J. Immunol. 186(5), 3248-3257 (2011
14. Sousa MM, Yan SD, Stern D, Saraiva MJ. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab. Invest. J. Tech. Methods Pathol. 80(7), 1101-1110 (2000
15. Monteiro FA, Cardoso I, Sousa MM, Saraiva MJ. In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE). FEBS Lett. 580(14), 3451-3456 (2006
16. Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J. Neurosci. 28(20), 5149-5158 (2008). Reports that V domain interacts with Ab.
17. Raucci A, Cugusi S, Antonelli A et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 22(10), 3716-3727 (2008). Discusses soluble RAG.E.
18. Kalea AZ, Reiniger N, Yang H, Arriero M, Schmidt AM, Hudson BI. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J. 23(6), 1766-1774 (2009
19. Mackic JB, Stins M, Mccomb JG et al. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J. Clin. Invest. 102(4), 734-743 (1998
20. Arancio O, Zhang HP, Chen X et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 23(20), 4096-4105 (2004
21. Yan SD, Zhu H, Zhu A et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 6(6), 643-651 (2000
22. Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer's disease: A progression factor for amyloid-beta-induced cellular perturbation? J. Alzheimers Dis. 16(4), 833-843 (2009
23. Baiguera S, Fioravanzo L, Grandi C, Di Liddo R, Parnigotto PP, Folin M. Involvement of the receptor for advanced glycation-end products (RAGE) in beta-Amyloid-induced toxic effects in rat cerebromicrovascular endothelial cells cultured in vitro. Int. J. Mol. Med. 24(1), 9-15 (2009
24. Ramasamy R, Yan SF, Schmidt AM. The RAGE axis and endothelial dysfunction: Maladaptive roles in the diabetic vasculature and beyond. Trends Cardiovasc. Med. 15(7), 237-243 (2005
25. Liu LP, Hong H, Liao JM et al. Upregulation of RAGE at the blood-brain barrier in streptozotocin-induced diabetic mice. Synapse 63(8), 636-642 (2009
26. Allmen EU, Koch M, Fritz G, Legler DF. V domain of RAGE interacts with AGEs on prostate carcinoma cells. Prostate 68(7), 748-758 (2008
27. Yamagishi S, Nakamura K, Matsui T. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharm. Res. 60(3), 174-178 (2009
28. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature. Circ. Res. 106(5), 842-853 (2010). Reviews the RAGE-ligand axis.
29. Yan SF, Naka Y, Hudson BI et al. The ligand/RAGE axis: Lighting the fuse and igniting vascular stress. Curr. Atheroscler. Rep. 8(3), 232-239 (2006). Discusses RAGE and vascular stress.
30. Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr. Opin. Investig. Drugs 10(7), 672-680 (2009
31. Hudson BI, Hofmann MA, Bucciarelli L et al. Glycation and diabetes: The RAGE connection. Curr. Sci. 83(12), 1515-1521 (2002
32. Hudson BI, Carter AM, Harja E et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 22(5), 1572-1580 (2008
33. Park H, Adsit FG, Boyington JC. The 1.5 A° crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J. Biol. Chem. 285(52), 40762-40770 (2010).Describes RAGE structure and its ligand binding.
34. Dattilo BM, Fritz G, Leclerc E, Kooi CW, Heizmann CW, Chazin WJ. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 46(23), 6957-6970 (2007
35. Haupt C, Bereza M, Kumar ST et al. Pattern recognition with a fibril-specific antibody fragment reveals the surface variability of natural amyloid fibrils. J. Mol. Biol. 408(3), 529-540 (2011
36. Chavakis T, Bierhaus A, Al-Fakhri N et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J. Exp. Med. 198(10), 1507-1515 (2003
37. Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J. Biol. Chem. 283(40), 27255-27269 (2008). Paper on RAGE as a pattern receptor.
38. Sarkany Z, Ikonen TP, Ferreira-Da-Silva F, Saraiva MJ, Svergun D, Damas AM. Solution structure of the soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem. 286(43), 37525-37534 (2011). Describes RAGE-ligand interactions.
39. Xue J, Rai V, Singer D et al. Advanced glycation end product recognition by the receptor for AGEs. Structure 19(5), 722-732 (2011
40. Gospodarska E, Kupniewska-Kozak A, Goch G, Dadlez M. Binding studies of truncated variants of the Ab peptide to the V-domain of the RAGE receptor reveal Ab residues responsible for binding. Biochim. Biophys. Acta 1814(5), 592-609 (2011). Discusses RAGE-Ab interaction.
41. Leclerc E, Sturchler E, Vetter SW. The S100B/RAGE axis in Alzheimer's disease. Cardiovasc. Psychiatry Neurol. 2010, 539581 (2010
42. Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J. Pharmacol. Sci. 97(3), 305-311 (2005
43. Querfurth HW, Laferla FM. Alzheimer's disease. N. Engl. J. Med. 362(4), 329-344 (2010
44. Hardy J. The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. J. Neurochem. 110(4), 1129-1134 (2009
45. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35(11 Suppl. 1), 2628-2631 (2004
46. Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid beta-peptide from brain: Transport or metabolism? Nat. Med. 6(7), 718-719 (2000
47. Shibata M, Yamada S, Kumar SR et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106(12), 1489-1499 (2000
48. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: The many roads to perdition. Neuron 43(5), 605-608 (2004
49. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2), 178-201 (2008
50. Deane R, Wu Z, Sagare A et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43(3), 333-344 (2004
51. Donahue JE, Flaherty SL, Johanson CE et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol. 112(4), 405-415 (2006
52. Miller MC, Tavares R, Johanson CE et al. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res. 1230, 273-280 (2008
53. Silverberg GD, Miller MC, Messier AA et al. Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging. J. Neuropathol. Exp. Neurol. 69(1), 98-108 (2010
54. Paris D, Patel N, Quadros A et al. Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci. Lett. 415(1), 11-16 (2007
55. Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-Amyloid peptides. J. Neurosci. Res. 85(6), 1194-1204 (2007
56. Benzing WC, Wujek JR, Ward EK et al. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging 20(6), 581-589 (1999
57. Sly LM, Krzesicki RF, Brashler JR et al. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. Bull. 56(6), 581-588 (2001
58. Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis. Assoc. Disord. 14(Suppl. 1), S47-S53 (2000
59. Wyss-Coray T. Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? Nat. Med. 12(9), 1005-1015 (2006
60. Frautschy SA, Yang F, Irrizarry M et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pahol. 152(1), 307-317 (1998
61. Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-Amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 28(33), 8354-8360 (2008
62. Grathwohl SA, Kalin RE, Bolmont T et al. Formation and maintenance of Alzheimer's disease beta-Amyloid plaques in the absence of microglia. Nat. Neurosci. 12(11), 1361-1363 (2009
63. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J. Neurosci. 29(38), 11982-11992 (2009
64. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-Amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 25(36), 8240-8249 (2005
65. El Khoury J, Toft M, Hickman SE et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13(4), 432-438 (2007
66. Giri R, Shen Y, Stins M et al. Beta-Amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am. J. Physiol. Cell Physiol. 279(6), C1772-C1781 (2000
67. Janelsins MC, Mastrangelo MA, Park KM et al. Chronic neuron-specific tumor necrosis factor-Alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am. J. Pathol. 173(6), 1768-1782 (2008
68. Park KM, Yule DI, Bowers WJ. Tumor necrosis factor-Alpha-mediated regulation of the inositol 1,4,5-Trisphosphate receptor promoter. J. Biol. Chem. 284(40), 27557-27566 (2009
69. Fan R, Xu F, Previti ML et al. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J. Neurosci. 27(12), 3057-3063 (2007
70. Mori T, Koyama N, Arendash GW, Horikoshi-Sakuraba Y, Tan J, Town T. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia 58(3), 300-314 (2010
71. Villarreal A, Aviles Reyes RX, Angelo MF, Reines AG, Ramos AJ. S100B alters neuronal survival and dendrite extension via RAGE-mediated NF-kappaB signaling. J. Neurochem. 117(2), 321-332 (2011
72. Deane R, Singh I, Sagare AP et al. Tertiary amide preferentially blocks Ab/RAGE interaction without causing toxicity. Presented at: Society for Neuroscience. Washington, DC, USA, 12-16 November 2011.
73. Deane R, Singh I, Sagare A et al. Tertiary amide reduced BACE1 activity and Ab production in a mouse model of AD. Presented at: Society for Neuroscience. San Diego, CA, USA, 13-17 November 2010.
74. Deane R, Singh I, Love R et al. Differential action of lipophilic and hydrophilic tertiary amide-based RAGE/Ab blockers in a mouse model of AD. Presented at: Society for Neuroscience. Chicago, IL, USA, 17-21 November 2009.
75. Deane R, Sagare A, Paquette N et al. Tertiary amide improves cerebral blood flow and behavioral performance in a mouse model of AD by blocking RAGE/Ab interaction. Presented at: Society for Neuroscience. Washington, DC, USA, 15-19 November 2008.
76. Deane R, Perry S, Sagare A et al. Tertiary amides block RAGE-mediated Ab transport into brain in a mouse model of AD. Presented at: Society for Neuroscience. Atlanta, GA, USA, 14-18 October 2006.
77. Deane R, Singh I, Sagare AP et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest. 122(4), 1377-1392 (2012). n Key paper on a type of tertiary amide as a RAGE blocker.
78. Sakatani S, Yamada K, Homma C et al. Deletion of RAGE causes hyperactivity and increased sensitivity to auditory stimuli in mice. PLoS ONE 4(12), e8309 (2009).